摘要
目的:探讨肾移植术后患者应用雷帕霉素(Rap)为基础免疫抑制药抗排斥治疗的疗效。方法:对16例肾移植术后患者应用Rap为基础免疫抑制药治疗排斥反应,对血肌酐恢复情况、移植肾存活及副作用作回顾分析。结果:16例肾移植术后即开始用药者11例移植肾功能恢复顺利,人肾存活良好;5例术后半年以上因移植肾功能减退而转换为Rap治疗患者中有4例血肌酐升高明显减缓。结论:雷帕霉素作为基础免疫抑制药治疗肾移植术后排斥反应有较好疗效。
Objective： To study the effects of anti-reject therapy in which rapamycin was used as the basic immuno-inhibitor after renal transplantation. Method： The clinical data of 16 patients after renal transplantation which were used rapamycin as basic immuno- inhibitor in anti-reject therapy, included the changes of blood creatinine, the recovery of graft-kidney and the side-effects were analyzed retrospectively. Result： The function of graft-kidney in 11 patients who took rapamycin right after transplantation recovered without a hitch. In the other 5 cases, whose function of graft-kidney declined switched to rapamycin over half of year since transplantation, the creatinine-increasing of blood was obviously slowered in 4 of 5 cases. Conclusion： Rapamycin is an effective drug as basic immuno-inhibitor in anti-reject therapy after renal transplantation.
出处
《中国药师》
CAS
2006年第10期943-945,共3页
China Pharmacist
关键词
肾移植
雷帕霉素
排斥反应
Renal transplantation
Rapamycin
Anti-rejection
